Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01219075 · ClinicalTrials.gov registry record · NA
Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer
A NA study, sponsored by University of Southern California.
- Completed
- Registry status
- NA
- Development phase
- 110
- Enrollment target
NCT01219075 is a NA study that has completed, run by University of Southern California. The registered enrollment target is 110 participants.
The verdict
NCT01219075, a NA study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- NA
- Development phase
- 110 participants
- Enrollment target
Study Summary
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of soy isoflavones supplements may prevent or treat early stage breast cancer. PURPOSE: This clinical trial studies soy isoflavones supplementation in treating women at high risk for or with breast cancer.
Interventions
- OTHER placebo
- OTHER questionnaire administration
- PROCEDURE biopsy
- PROCEDURE magnetic resonance imaging
- DIETARY_SUPPLEMENT soy isoflavones
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2010-07-01 |
| Est. Completion | 2022-11-24 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01219075
The ClinicalTrials.gov registry entry for NCT01219075 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which placebo is the first listed.
NCT01219075 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01219075 about?
NCT01219075 is a clinical study titled "Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer". RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of soy isoflavones supplements may prevent or treat early stage breast cancer. PURPOSE: This clinical trial studies soy isoflavones supplementation in treating women at high risk for or with breast cancer.
What is the current status of trial NCT01219075?
This trial is currently completed. It is a NA study. The enrollment target is 110 participants. The study started on 2010-07-01. Estimated completion is 2022-11-24.
What interventions are being tested in trial NCT01219075?
The interventions under investigation include: placebo (OTHER), questionnaire administration (OTHER), biopsy (PROCEDURE), magnetic resonance imaging (PROCEDURE), soy isoflavones (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01219075?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.